COVID-19 ReMap CAP Study

Hello, Matt Thomas is my name and I'm a Consultant in Intensive Care here at Southmead Hospital, and I'm the Principal Investigator for the ReMap CAP study, which is currently recruiting patients in the Intensive Care Unit.

ReMap CAP is a really exciting study that's now running in 13 countries worldwide, from North America, through Europe, down into Australia and New Zealand. And the reason it's exciting for us is the trial design is very new. It's called an adaptive trial and that means that we can test multiple different interventions simultaneously, and retain a lot of flexibility about the interventions that are available for patients here at Southmead, and those that they might be able to benefit from.

So the study is designed so that the interventions that look beneficial are selected out and patients have a greater chance of receiving them, and interventions that are maybe not so beneficial tend to be lost from the study early.

So we have a number running here. We have antiviral interventions, we have those that modify the immune system, we have anticoagulation and we have steroids. And one that is coming in the UK, but we are not participating in, is the immunoglobulin domain.

So as of today we have ten patients recruited and I think that's a reflection of the very hard work that the COVID research team are doing, communicating with patients and their families to make sure we get as many patients recruited as possible to this important work.